Email updates

Keep up to date with the latest news and content from Lipids in Health and Disease and BioMed Central.

Open Access Highly Accessed Review

Nanostructured Lipid Carriers: A potential drug carrier for cancer chemotherapy

Subramanian Selvamuthukumar* and Ramaiyan Velmurugan

Author Affiliations

Department of Pharmacy, Annamalai University, Annamalai nagar, 608002, Tamilnadu, India

For all author emails, please log on.

Lipids in Health and Disease 2012, 11:159  doi:10.1186/1476-511X-11-159

Published: 20 November 2012

Abstract

Nanotechnology having developed exponentially, the aim has been on therapeutic undertaking, particularly for cancerous disease chemotherapy. Nanostructured lipid carriers have attracted expanding scientific and commercial vigilance in the last couple of years as alternate carriers for the pharmaceutical consignment, particularly anticancer pharmaceuticals. Shortcomings often came across with anticancer mixtures, such as poor solubility, normal tissue toxicity, poor specificity and steadiness, as well as the high incidence rate of pharmaceutical resistance and the rapid degradation, need of large-scale output procedures, a fast release of the pharmaceutical from its carrier scheme, steadiness troubles, the residues of the organic solvents utilized in the output method and the toxicity from the polymer with esteem to the carrier scheme are anticipated to be overcome through use of the Nanostructured Lipid Carrier. In this review the benefits, types, drug release modulations, steadiness and output techniques of NLCs are discussed. In supplement, the function of NLC in cancer chemotherapy is presented and hotspots in research are emphasized. It is foreseen that, in the beside future, nanostructured lipid carriers will be further advanced to consign cytotoxic anticancer compounds in a more efficient, exact and protected manner.

Keywords:
Nanostructured lipid carriers; cancer chemotherapy; controlled drug release; increased drug load; stability; tissue target